Page last updated: 2024-09-03

ulipristal acetate and vilaprisan

ulipristal acetate has been researched along with vilaprisan in 3 studies

Compound Research Comparison

Studies
(ulipristal acetate)
Trials
(ulipristal acetate)
Recent Studies (post-2010)
(ulipristal acetate)
Studies
(vilaprisan)
Trials
(vilaprisan)
Recent Studies (post-2010) (vilaprisan)
37641347191019

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bumbuliene, Ž; Costa, AR; Gemzell-Danielsson, K; Heikinheimo, O; Heweker, A; Hudeček, R; Jacquemyn, Y; Melis, GB; Parashar, P; Rechberger, T; Sánchez, AC; Seitz, C; van Aken, B; Zatik, J1
Belland, L; Leyland, N; Murji, A; Singh, SS; von Riedemann, S1
Ajossa, S; Corda, V; Giancane, E; Mais, V; Marotto, MF; Melis, GB; Neri, M; Paoletti, AM; Pilloni, M; Piras, B; Saba, A1

Reviews

2 review(s) available for ulipristal acetate and vilaprisan

ArticleYear
The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
    American journal of obstetrics and gynecology, 2018, Volume: 218, Issue:6

    Topics: Contraceptive Agents, Female; Disease Management; Estrenes; Female; Forecasting; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Oximes; Population Growth; Receptors, Progesterone; Steroids; Uterine Neoplasms

2018
Vilaprisan for treating uterine fibroids.
    Expert opinion on investigational drugs, 2018, Volume: 27, Issue:5

    Topics: Animals; Female; Humans; Leiomyoma; Norpregnadienes; Receptors, Progesterone; Steroids; Time Factors; Uterine Hemorrhage; Uterine Neoplasms

2018

Trials

1 trial(s) available for ulipristal acetate and vilaprisan

ArticleYear
Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids.
    Contemporary clinical trials, 2017, Volume: 55

    Topics: Adolescent; Adult; Contraceptive Agents, Female; Double-Blind Method; Drug Administration Schedule; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Quality of Life; Research Design; Steroids; Young Adult

2017